Pharma’s next IP arms race isn’t about inventing from scratch—it’s about designing around.
If you’re building a pipeline in 2026, you’re not just competing on efficacy, safety, and manufacturing. You’re competing on patent geography: where your product…

Formulation Forensics: The Hidden Detective Work Inside Drug Patent Claims
Most people read drug patents like they’re looking for the “active ingredient.” But the real story is often buried in the inactive—the excipients, the process steps, the ratios,…

The biosimilar “patent dance” isn’t a formality—it’s the first move in a multi-year chess match.
If you’re a biologics innovator or a biosimilar applicant, the rules of engagement are well known. What’s less discussed is how the timing, sequencing, a…

Generic manufacturers don’t “wait” for exclusivity—they engineer it.
In the Paragraph IV world, the 180-day exclusivity clock doesn’t just measure time. It measures execution. It rewards the teams that can turn a legal filing into a manufacturing adv…

The Patent Dance is a courtroom choreography. But for biologics and biosimilars, the real game is timing, leverage, and precision.
If you’re a biosimilar applicant, you already know the headlines: the “patent dance” under the BPCIA can decide whether y…

Big Pharma loves to talk about pipelines. But the real competitive edge in drug development isn’t the next press release—it’s the next data point.
Drug patent intelligence is becoming the quiet advantage in supply chain forecasting, and it’s starting t…

Patent cliffs aren’t just a legal event—they’re a supply-chain event.
When a blockbuster drug’s exclusivity expires, the market doesn’t simply “open.” It changes. Pricing shifts. Manufacturing capacity reallocates. Contract terms get renegotiated. Fo…

Generic drug makers are facing a quiet margin squeeze—and it’s not just one problem. It’s a stack of pressures hitting at the same time: pricing pressure, higher costs, slower approvals, and a regulatory environment that can turn “routine” launches int…

Branded pharma’s revenue model is under siege—and it’s not just one problem. It’s a stack.
In a recent piece from DrugPatentWatch, the argument is blunt: there are “8 brutal problems” that are steadily eroding the traditional playbook for branded drug …

Generic drug competition isn’t won in the lab—it’s won in the Orange Book.
If you’ve ever wondered how some generic manufacturers seem to “arrive” at market faster than others—often with fewer surprises, cleaner launch timelines, and more predictable…